You are viewing an incomplete version of our website. Please click to reload the website as full version.

VEGFR-1/2 (Haemangioblast and Stem Cell Marker) (AA 800-900), (Internal Region) antibody

Details for Product No. ABIN251660, Supplier: Log in to see
Internal Region, AA 800-900
Immunocytochemistry (ICC), Immunofluorescence (IF), Western Blotting (WB)
Log in to see
Supplier Product No.
Log in to see

Get this product for free

It's quick and easy to submit your validation proposal. I want to validate this product

Learn more

Available images

Immunogen A synthetic peptide made to an internal region of the mouse VEGF Receptor 1 protein (between residues 800-900). There is 87% identity between the immunogen used for this production and the VEGF Receptor 2 protein. Immunogen sequence has 100% homology to mouse and rat.Marker Endothelial Cell Marke
Specificity This antibody targets VEGFR-1 but has significant cross-reactivity with the VEGFR-2 protein.
Purification affinity purified
Background Receptors for VEGF, VEGFB and PGF have a tyrosine-protein kinase activity. TheVEGF-kinase ligand/receptor signaling system plays a key role in vascular developmentand regulation of vascular permeability. VEGF and its high-affinity binding receptors, the tyrosine kinases FLK1 and FLT1, arethought to be important for the development of embryonic vasculature. It has beenshown that an alternately spliced form of FLT1 produces a soluble protein, termedsFLT1, which binds vascular endothelial growth factor with high affinity, playing aninhibitory role in angiogenesis. Alternate Names: anti-VEGFR1 antibody, anti-VEGFR 1 antibody, anti-Vascular permeability factorreceptor antibody, anti-Tyrosine-protein kinase receptor FLT antibody, anti-Flt-1antibody, anti-Tyrosine-protein kinase FRT antibody, anti-Fms-like tyrosine kinase 1antibody, anti-Embryonic receptor kinase 2 antibody, anti-VEGFR2 antibody,anti-VEGFR 2 antibody, anti-Protein-tyrosine kinase receptor flk-1 antibody, anti-Fetalliver kinase 1 antibody, anti-Kinase NYK antibody, anti-FLK1 antibody, anti-KDRantibody, anti-Kinase insert domain receptor antibody, anti-KRD1 antibody, anti-Ly73antibody, anti-Protein tyrosine kinase receptor FLK1 antibody, anti-Vascular endothelialgrowth factor receptor 2 antibody.
Gene Symbol: FLT1
Gene ID 2321
UniProt P35969
Application Notes This VEGF Receptor 1 antibody is useful for Western blot, where a band is seen at ~180-230 kDa (the theoretical molecular weight of mouse VEGFR1 is ~150 kDa and human VEGFR1 is ~151 kDa). The difference in MWs is likely due to glycosylation or other post translational modifications. With CSF-1R/VEGFR2 chimera transfected lysates a doublet is seen at ~150 kDa representing VEGFR-2. An unknown band is also seen at ~50 kDa. Optimal working dilutions should be determined by the investigator.
Recommended dilutions: Immunocytochemistry/Immunofluorescence 1:500, Western Blot 1:100-1:2000
Protocol Protocol specific for VEGF Receptor 1 Antibody Western Blot Protocol
1. Perform SDS-PAGE (3-8 %) on samples to be analyzed, loading 50 µg of total protein per lane.
. Transfer proteins to Nitrocellulose according to the instructions provided by the manufacturer of the transfer apparatus.
. Stain the blot using ponceau S for 1-2 minutes to access the transfer of proteins onto the nitrocellulose membrane. Rinse the blot in water to remove excess stain and mark the lane locations and locations of molecular weight markers using a pencil.
. Rinse the blot in TBS for approximately 5 minutes.
. Block the membrane using 5 % non-fat dry milk + 0.5 % BSA in TBS for 1 hour.
. Dilute the rabbit anti-VEGFR1 primary antibody in blocking buffer and incubate 2 hours at room temperature.
. Wash the membrane in water for 5 minutes and apply the diluted rabbit-IgG HRP-conjugated secondary antibody in blocking buffer (as per manufacturer's instructions) and incubate 1 hour at room temperature.
. Wash the blot in TBS containing 0.05-0.1 % Tween-20 for 10-20 minutes.
. Wash the blot in type I water for an additional 10-20 minutes (this step can be repeated as required to reduce background).
. Apply the detection reagent of choice in accordance with the manufacturer's instructions (Amersham's ECL is the standard reagent used).Note: Tween-20 can be added to the blocking buffer at a final concentration of 0.05-0.2 %, provided it does not interfere with antibody-antigen binding.
Restrictions For Research Use only
Format Liquid
Concentration 1 mg/mL
Buffer Tris-glycine, 150 mM NaCl, Sodium Azide
Preservative Sodium azide
Precaution of Use WARNING: Reagents contain sodium azide. Sodium azide is very toxic if ingested or inhaled. Avoid contact with skin, eyes, or clothing. Wear eye or face protection when handling. If skin or eye contact occurs, wash with copious amounts of water. If ingested or inhaled, contact a physician immediately. Sodium azide yields toxic hydrazoic acid under acidic conditions. Dilute azide-containing compounds in running water before discarding to avoid accumulation of potentially explosive deposits in lead or copper plumbing.
Handling Advice Do not freeze.
Storage 4 °C
Supplier Images
Western Blotting (WB) image for anti-VEGFR-1/2 (Haemangioblast and Stem Cell Marker) (AA 800-900), (Internal Region) antibody (ABIN251660) Chimeric CSF-1R/VEGFR-2 detection in transfected lysates.
Product cited in: Takahashi, Hattori, Iwamatsu, Takizawa, Shibuya: "A novel snake venom vascular endothelial growth factor (VEGF) predominantly induces vascular permeability through preferential signaling via VEGF receptor-1." in: The Journal of biological chemistry, Vol. 279, Issue 44, pp. 46304-14, 2004

Rahimi, Dayanir, Lashkari: "Receptor chimeras indicate that the vascular endothelial growth factor receptor-1 (VEGFR-1) modulates mitogenic activity of VEGFR-2 in endothelial cells." in: The Journal of biological chemistry, Vol. 275, Issue 22, pp. 16986-92, 2000

Background publications Gluzman-Poltorak, Cohen, Shibuya, Neufeld: "Vascular endothelial growth factor receptor-1 and neuropilin-2 form complexes." in: The Journal of biological chemistry, Vol. 276, Issue 22, pp. 18688-94, 2001